Oklahoma-UT Southwestern Hemostasis Consortium

描述(由申请人提供) 俄克拉荷马-德克萨斯大学西南止血联盟在网络活动的头四年一直是TMH CTN的积极参与者。我们联盟的研究人员在致力于TIP、IIP、血友病、儿科和HIT方案开发的小组中发挥了领导作用。此外，我们联盟的两个网站都非常有效地在初始网络中招募了患者。临床试验，PLADO。对于TTP，乔治博士是这个小组委员会的最初联合主席，并且仍然是STAR试验发展的领导者。他在俄克拉何马州的同事Sara Vesely博士和Dee Terrell女士也在STAR试验的开发中发挥了关键作用：Vesely博士负责生物统计学分析，Terrell女士作为开发这项研究的两名关键临床试验协调员之一。乔治博士和布坎南博士都是ITP小组委员会的领导人，致力于使用一种类似TPO的试剂为儿童ITP制定方案。布坎南博士是儿科小组委员会的最初负责人，并为制定决策分析方案做出了贡献，以确定儿童ITP的关键研究问题。Buchanan博士和我们的两名初任教员，德克萨斯大学西南分校的Janna JourneyCake博士和俄克拉何马州的Kapil Saxena博士为RICH研究的发展做出了关键贡献。当这项研究开始时，我们预计将成为临床试验的主要地点之一。布坎南博士和乔尼利克博士还非常积极地参与了这项研究，以评估RTPA在减少血友病患者中心静脉通路设备感染方面的作用。这一直是乔尼·凯奇博士和布坎南博士的主要研究兴趣。德克萨斯大学西南分校的Ravi Sarode博士一直是确定与肝素相关的血栓栓塞症频率的方案开发的领导者，这是一项热门研究，他预计将成为这项研究的主要登记中心。TMH CTN通过许多协作互动，拉近了我们两个大学中心的距离。过去四年的一个有价值的结果是，合作关系扩展到我们项目中的初级教员和实习生。

DESCRIPTION (provided by applicant) The Oklahoma-UT Southwestern Hemostasis Consortium has been an active participant of the TMH CTN for the first four years of the network activity. Investigators from our consortium have had leading roles in the subgroups devoted to TIP, IIP, hemophilia, pediatric and HIT protocol development. In addition, both sites of our consortium have very effectively enrolled patients in the initial network .clinical trial, PLADO. For TTP, Dr. George was the initial co-chair of this subcommittee and remains a leader in the development of the STAR trial. His colleagues at Oklahoma, Dr. Sara Vesely and Ms. Dee Terrell, have also contributed in key roles to the STAR trial development: Dr. Vesely with biostatistical analysis and Ms. Terrell as one of the two key clinical trial coordinators developing this study. Both Drs. George and Buchanan have been leaders in the ITP subcommittee, working to develop a protocol for childhood ITP using a TPO-mimetic agent. Dr. Buchanan was the initial leader of the pediatric subcommittee, and has contributed to the development of a decision analysis protocol to determine the critical research questions for childhood ITP. Dr. Buchanan and two of our beginning faculty, Dr. Janna Journeycake at UT Southwestern and Dr. Kapil Saxena of Oklahoma have been key contributors to the development of the RICH study. When this study opens we anticipate being one of the leading sites for the clinical trial. Drs. Buchanan and Journeycake have also been very active in the development of the study to evaluate the role of rTPA in reducing central venous access device infection in patients with hemophilia. This has been a major research interest of Drs. Journeycake and Buchanan. Dr. Ravi Sarode of UT Southwestern has been a leader in the development of the protocol to determine the frequency of thromboembolism related to heparin, the HOT study, and he anticipates being the lead enrolling center for this study. The TMH CTN has brought our two university centers closer together with many collaborative interactions. A valuable outcome of the past four years has been the extension of collaborative relationship to the junior faculty members and trainees in our programs.